NCT00831779View on ClinicalTrials.gov

Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin

Tablets, Oral, 5 mg, once daily, 12 weeks

DRUG

Placebo

Tablets, Oral, 0 mg, Once daily, 12 weeks

Trial Locations (3)

19140

Temple University General Clinical Research Center, Philadelphia

70808

Pennington Biomedical Research Center, Baton Rouge

92161

Va San Diego Healthcare System, San Diego

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Astra Zeneca, Bristol-Myers Squibb

OTHER

lead

AstraZeneca

INDUSTRY